Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Earlier this month, Pfizer’s chairman and CEO, Ian Read, said he was considering selling the company’s Consumer Healthcare business, or possibly spinning it off.
Stryker picked up controlling interest in Vexim, a French medical device company that specializes in the minimally invasive treatment of vertebral fractures.
Danish company Ambu plopped down $265M to acquire Germany-based Invendo Medical, a privately-held medtech company that develops single-use high definition endoscopy products.
scPharmaceuticals filed recently with the SEC regarding its plans for an IPO.
WuXi AppTec, a China CRO/CMO, will acquire ResearchPoint Global, of Texas, a global clinical-stage contract research company, to extend the reach of its own clinical CRO coverage.
TPG Capital has acquired all the outstanding shares of Exactech common stock for $42 per share.
Two privately-held biotechs have merged to tackle recurrent C. difficile infections.
GIMDx of Carlsbad, California acquired exclusive China OEM and distribution rights to oncology diagnostic products made by IncellDx, a Menlo Park company.
Two factors have increased speculation that Smith & Nephew may be ready for a takeover.